Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | USP30 | Q70CQ3 | 9/20 | 0.78 |
| ▸ | ANO1 | Q5XXA6 | 2/20 | 0.62 |
| ▸ | HDAC4 | P56524 | 2/20 | 0.55 |
| ▸ | HDAC6 | Q9UBN7 | 2/20 | 0.55 |
| ▸ | PARP1 | P09874 | 2/20 | 0.54 |
| ▸ | GABRA5 | P31644 | 1/20 | 0.51 |
| ▸ | CNR1 | P21554 | 1/20 | 0.48 |
| ▸ | CNR2 | P34972 | 1/20 | 0.48 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30089220 | 1.00 | USP30 (0.78) | USP30ANO1HDAC4HDAC6PARP1 | |
| SCHEMBL5145035 | 0.88 | USP30 (0.82) | USP30ANO1HDAC4HDAC6PARP1 | |
| SCHEMBL18124126 | 0.88 | USP30 (1.00) | USP30ANO1HDAC4HDAC6PARP1 | |
| SCHEMBL17927270 | 0.87 | USP30 (0.74) | USP30ANO1HDAC4HDAC6PARP1 | |
| SCHEMBL23713389 | 0.86 | USP30 (0.72) | USP30ANO1HDAC4HDAC6PARP1 | |
| SCHEMBL29842299 | 0.86 | USP30 (0.72) | USP30ANO1HDAC4HDAC6PARP1 | |
| SCHEMBL29842139 | 0.86 | USP30 (0.72) | USP30ANO1HDAC4HDAC6PARP1 | |
| SCHEMBL29136109 | 0.84 | USP30 (0.70) | USP30ANO1HDAC4HDAC6PARP1 | |
| SCHEMBL30088837 | 0.83 | USP30 (0.69) | USP30ANO1HDAC4HDAC6PARP1 | |
| SCHEMBL27177195 | 0.83 | USP30 (0.56) | USP30 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-117321042-A | Oxodihydro indole compounds for the treatment of inflammatory diseases or cancers | 豪夫迈·罗氏有限公司 | 2023-12-29 | — | — | CN | disclosed |